Macchia Alejandro, Mariani Javier, Comignani Pablo Dino, Fuselli Juan José, Monte Simona, Romero Marilena, Tognoni Gianni
Fundación GESICA (Clinical Investigation Study Group in Argentina), Avenida Rivadavia 2358, 1 piso oficina 4 (C1034ACP) Buenos Aires, Argentina.
Expert Rev Cardiovasc Ther. 2009 Feb;7(2):139-45. doi: 10.1586/14779072.7.2.139.
In patients with heart failure, anemia is highly prevalent and associated with impaired outcomes. These clinical observations necessitate the realization of pharmacologic interventions to mitigate the effects of anemia and a number of available agents are being tested in large, randomized clinical trials. However, from the pathophysiologic point of view, anemia is multifactorial and difficult to attribute to a single mechanism. Moreover, classic indicators for the identification of etiology and pathways have been found to be less accurate than expected. For these reasons future clinical trials must be designed to be able to elucidate the complexity of mechanisms and the implications for treatment strategies.
在心力衰竭患者中，贫血极为普遍且与不良预后相关。这些临床观察结果使得有必要实施药物干预以减轻贫血的影响，并且一些现有药物正在大型随机临床试验中接受测试。然而，从病理生理学角度来看，贫血是多因素的，难以归因于单一机制。此外，已发现用于确定病因和途径的经典指标不如预期准确。基于这些原因，未来的临床试验必须设计成能够阐明机制的复杂性以及对治疗策略的影响。
